Pacylex Pharmaceuticals Announces Publication in Nature Communications of a New Target for Therapeutic Intervention in Hematologic Malignancies and Preclinical Results of a First-in-Class Therapy
Edmonton, Alberta, Canada, October 22, 2020
To view the full announcement, including downloadable images, bios, and more, click here.
- Data published in Nature Communications shows NMT inhibitor effective against many cancer cell lines, especially blood cancers including lymphoma and leukemia
- Pacylex was founded on the insight that there is a connection between myristoylation and cancer, which presented a target that had never been fully explored for potential human therapy.
- Establishes proof-of-concept for NMT inhibitors as potential cancer therapeutics and supports the continued preparation for the first human clinical trial set to begin in early 2021.
Click image above to view full announcement.
Pacylex is a pre-clinical pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, and is headquartered in Edmonton, Alberta, Canada. Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta, connecting myristoylation to cancer, with a family of high quality myristoylation inhibitors Pacylex licensed the molecules from the University of Dundee in 2015. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling us to exploit NMTs as new clinical targets for cancer treatment. Pacylex completed GLP toxicology on PCLX-001 and expects to file soon for regulatory authorization to commence clinical studies in Canada in early 2021 in diffuse large B-cell lymphoma and solid tumors.
Michael Weickert Ph.D
Distributed by: Reportable, Inc.